Psoriasis roundtable: 60.7% scalp response and coverage barriers
![<![CDATA[Psoriasis Roundtable Examines Barriers to Sustained Biologic Care]]>](/media/b6/b6c58a52a8c87b24.1280.webp)
By Olivia Hart
Tildrakizumab produced at least a 90% improvement in Psoriasis Scalp Severity Index (PSSI) scores in 60.7% of scalp psoriasis patients at week 16, climbing to about 65% at week 52 — the sharpest efficacy figure presented at a Dermatology Times Case-Based Roundtable on October 29, 2026, in San Diego, California.
The meeting put a 12-week dosing interval, an office injection and a lapsed formulary on equal footing as drivers of sustained biologic care in plaque psoriasis.
Moderator Alvin Coda, MD, a dermatologist at Scripps in Rancho Bernardo, ran 3 patient scenarios: whether a 39-year-old roofing contractor with 15% body surface area (BSA) involvement and a body mass index of 33 should move off topicals; how to support a 72-year-old retired school administrator who missed apremilast doses; and how to treat a 34-year-old emergency department nurse whose scalp and nail disease outlasted 6 months of secukinumab.
What makes a patient ready for systemic therapy beyond BSA?
The contractor's plaques covered roughly 15% BSA, mainly trunk and arms, worsened by sun exposure and sweating, with intermittent irritation and pruritus. Hypertension, a BMI of 33 and a family history of premature coronary artery disease sat alongside inconsistent topical corticosteroid use and no prior biologic.
Clinicians flagged practicality: topicals work poorly on widespread plaques across hard-to-reach areas such as the back, and one participant proposed using topicals as a bridge while discussing oral and injectable systemic options. Some patients hesitate to start biologics over immunosuppression concerns or misinformation about adverse effects.
Coda walked the group through International Psoriasis Council criteria for systemic therapy candidacy — psoriasis involving more than 10% BSA, high-impact anatomical sites, or inadequate response to topicals. The group agreed extent alone should not decide; quality-of-life impairment, occupational limitations, prior topical failure and psoriatic arthritis screening belong in the same assessment.
When do IL-17 and IL-23 inhibitors actually differ?
Selection turned on dosing frequency, patient age, occupational travel, injection preferences, infection concerns and concomitant inflammatory conditions. Coda reviewed analyses of secukinumab, ustekinumab, etanercept, tildrakizumab, brodalumab and ixekizumab, noting obesity, diabetes, hypertension and metabolic syndrome may influence efficacy differently across agents.
His read: metabolic syndrome has variably attenuated responses to some biologics, while tildrakizumab analyses suggested sustained efficacy regardless of metabolic syndrome status. Coda cautioned against interpreting "improvements in psoriasis as evidence of cardiovascular risk reduction," noting the link between chronic inflammation and cardiovascular disease still needs research on cardiovascular events.
Can a 12-week interval keep an older patient on treatment?
The 72-year-old retired school administrator carried longstanding plaque psoriasis across about 12% BSA — elbows, knees and lower back — with pruritus rated 6 out of 10 and knee plaques that disturbed walking and sleep. Osteoarthritis, well-controlled type 2 diabetes and impaired dexterity complicated self-application of topicals she had used alongside roflumilast. Apremilast had been prescribed but frequently missed because of its twice-daily schedule.
Clinicians proposed involving family, arranging medication assistance, or switching to a less frequent biologic. The dermatologist chose tildrakizumab, an IL-23 inhibitor given in clinic with maintenance injections every 12 weeks, opening chances to reinforce adherence and assess response.
One participant framed the choice plainly: "The most effective treatment is ultimately one the patient can consistently receive."
Real-world persistence analyses favored tildrakizumab: its users remained on therapy longer than users of several other psoriasis agents across follow-up extending to 30 months. The roundtable stopped short of blaming administration setting alone, calling the data observational. In-office therapy carries its own friction, including private practices that purchase biologics before reimbursement arrives, missed appointments, acquisition costs and reimbursement uncertainty.
What breaks continuity between visits?
Participants described treatment interruptions after insurers unexpectedly discontinued coverage for previously approved biologics. For older adults entering Medicare, they recommended checking formularies and prescription drug coverage before selecting or continuing a drug.
Nonadherence also surfaced from misread intervals: a patient may take a q8-week injection every 2 calendar months, or a q12-week injection every 3 months, and that drift accumulates into delayed doses and recurrence. Others stopped treatment after clearing their skin and flared again. Education, explicit scheduling instructions and follow-up after control were the fixes.
How do scalp and nail findings change the plan?
The 34-year-old emergency department nurse had about 15% BSA involved, including scalp and fingernails, with nail changes causing discomfort at work and denting her confidence. Rotating 12-hour shifts, irregular sleep, stress-related flares, anxiety and migraines complicated monthly secukinumab injections.
Clinicians recommended simpler dosing and office administration, and one participant had patients enter future injection dates into their phone calendars during appointments. The selected approach was a q12-week injection she could schedule around her shifts.
Scalp and nail involvement can inflict disproportionate physical and psychological distress even when BSA looks modest, and some patients refuse systemic therapy because they read their disease as too limited. Clinicians urged asking directly about genital and intertriginous disease, which patients rarely volunteer, and evaluating nail and scalp disease for psoriatic arthritis.
When is a biologic ready to be judged, or switched?
Several clinicians reassess roughly 3 months after starting a biologic and allow up to 6 months before deciding whether it delivered an adequate response. Counseling covered the targeted immunomodulatory effects of newer agents and their adverse effects.
Site-specific trial numbers set the efficacy frame: tildrakizumab cleared the PSSI 90% benchmark in 60.7% at week 16 and about 65% at week 52, while nail responses lagged, with roughly 25% reaching at least a 75% NAPSI improvement at week 28 and about 40% at week 52, reflecting nail growth time. Coda warned against cross-study comparisons given differing populations, outcome measures and trial designs, and pressed for Psoriasis Area and Severity Index (PASI) and Investigator's Global Assessment alongside post hoc analysis caveats.
What does this change for a dermatologist choosing between IL-17 and IL-23?
It moves the choice beyond a comorbidity scorecard: the deciding variables are whether the patient can obtain the drug, afford it, administer it and keep taking it. A 12-week interval, in-office administration and a formulary check at Medicare transition carry as much weight as the metabolic-response data.
Clinicians left the roundtable wanting evidence in difficult-to-treat subtypes such as palmoplantar psoriasis, alongside emerging oral therapies aimed at the IL-23 and TYK2 pathways.
Source: dermatologytimes.com
Olivia Hart
Show full bio
News editor covering technology and product news in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.